Tonix Pharmaceuticals Stock price Nasdaq

Equities

TNXP

US8902608624

Biotechnology & Medical Research

End-of-day quote Nasdaq 06:00:00 2024-02-04 pm EST 5-day change 1st Jan Change
0.3222 USD -2.36% Intraday chart for Tonix Pharmaceuticals +2.32% -20.05%
Sales 2023 * 10.3M Sales 2024 * 22.8M Capitalization 19.16M
Net income 2023 * -115M Net income 2024 * -78M EV / Sales 2023 * 1.86 x
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 0.84 x
P/E ratio 2023 *
-0.04 x
P/E ratio 2024 *
-0.1 x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float 99.99%
More Fundamentals * Assessed data
Dynamic Chart
Tonix Pharmaceuticals Gets Rare Pediatric Disease Label For TNX-2900 to Treat Prader-Willi Syndrome MT
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues At the American Chemistry Society Spring 2024 Meeting CI
Tonix Pharmaceuticals Reports Improvement in ?Brain Fog,? in Fibromyalgia Patients Treated with Tonmya? in Resilient, an Nda-Enabling Phase 3 Clinical Trial CI
Tonix Pharmaceuticals Holding Corp. Announces Publication in Psychiatry Research Showing Activity of Bedtime TNX-102 SL on PTSD Symptoms and Sleep Quality in Military-Related PTSD at Four Weeks of Therapy CI
Tonix Pharmaceuticals Announces Translation of Preclinical Pharmacokinetic Parameters of TNX-1500 (Fc-modified humanized anti-CD40L mAb) Supports Monthly i.v. Dosing in Humans CI
Tonix Pharmaceuticals Completes Clinical Stage of Phase 1 Trial for TNX-1500 (Fc-Modified Humanized Anti-CD40L mAb) in Healthy Volunteers CI
Tonix Pharmaceuticals Announces Positive Results from Clinical Pharmacokinetic Bridging Study of Tonmya? to Support Development and Partnering in Japan and China CI
Tonix Pharmaceuticals Reports Positive Phase 3 Study Results for Its Non-Opioid Painkiller in Late December CI
Tonix Pharmaceuticals Hosted KOL Webinar on Positive Phase 3 Fibromyalgia Trial for Tonmya?, Plans to File NDA for FDA Approval in Second Half of 2024 CI
Tonix Pharmaceuticals Holding Corp. Announces FDA IND Clearance for DoD Funded Trial of TNX-102 SL for the Reduction of Acute Stress Response and Prevention of PTSD CI
More news
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch (sumatriptan injection) 3 mg and Tosymra (sumatriptan nasal spray) 10 mg. Its portfolio consists of central nervous system (CNS), rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmune diseases and cancer. Its infectious disease portfolio includes a vaccine in development to prevent smallpox and mpox, vaccines to prevent COVID-19, a platform to make fully human monoclonal antibodies (mAbs), to treat COVID-19 and humanized anti-SARS-CoV-2 mAbs. Its product candidates include TNX-102 SL, TNX-4300, TNX-1900, TNX-601 ER and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.3269 USD
Average target price
5.5 USD
Spread / Average Target
+1,582.47%
Consensus